Skip to Content
Last Updated: 04/25/2012

Selected Major Accomplishments of CTEP:
2005 – 2011

  • Over 30 Practice-Changing Clinical Trials including therapeutic agents and other modalities, with 4 announced in first 6 months of 2011

    • ACOSOG-Z0011 — Surgery: SLND not inferior to Axillary Dissection in SLN+ BC
    • NCIC-CTG MA.20 — RT: Regional Nodal RT reduces LR & improves DFS in Node+ BC
    • COG-AALL0232 — Pediatrics: High Dose MTX improves EFS in pediatric ALL
    • RTOG-94-08 — Multimodality: Short-term ADT with RT improves OS in prostate cancer
  • Over 10 FDA Indications — New Oncology Agents (Yr FDA Approval)

    • Bevacizumab — CRC (2006); NSCLC (2006); Renal Cell Cancer (2009)
    • Imatinib mesylate — Pediatric CML (2006); Adjuvant GIST (2008)
    • Nelarabine — T-ALL and T-LBL (2005)
    • Rituximab — Diffuse Large B-cell Lymphoma (2006); Follicular NHL (2006)
    • Trastuzumab — Adjuvant Therapy for Early-stage Her2+ Breast Cancer (2006)
    • Thalidomide — Newly Diagnosed Multiple Myeloma (2006)
    • Anti-GD2 Antibody (ch14.18) in Neuroblastoma (BLA Currently in Preparation)
  • Examples: New Indications Generic Agents (Yr Publication/Press Release)

    • Daunorubicin in AML (2009); Dexamethasone in Multiple Myeloma (2007)